U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 12 results

Status:
US Approved Rx (2023)
First approved in 2013

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Dabrafenib is a selective, orally bioavailable inhibitor of Mutant BRAF protein kinase with potential antineoplastic activity. Dabrafenib inhibits BRAF kinases with in vitro IC50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V...
Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)

Conditions:

Dimethylzinc is an important reagent in organic synthesis, for example in the enantioselective alkylation of carbonyls and imines and in cyclopropanation reactions.
Status:
US Previously Marketed
First approved in 1947

Class (Stereo):
CHEMICAL (ACHIRAL)

Conditions:

SODIUM GLYCOLATE, a sodium salt of carboxymethyl ether, is used as a pharmaceutical grade dissolution excipient for solid dosage forms. It absorbs water rapidly, resulting in swelling which leads to the rapid disintegration of tablets and capsules. W...
Status:
US Approved Rx (2023)
First approved in 2013

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Dabrafenib is a selective, orally bioavailable inhibitor of Mutant BRAF protein kinase with potential antineoplastic activity. Dabrafenib inhibits BRAF kinases with in vitro IC50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V...

Showing 1 - 10 of 12 results